SCHEMBL10243848

SCHEMBL10243848

COC(=O)NCCN[C@@H](C)c1cccc(O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 3/20 0.44
CD274 Q9NZQ7 2/20 0.41
HIF1A Q16665 4/20 0.40
ADRB1 P08588 2/20 0.40
ADRA1A P35348 2/20 0.40
ADRB2 P07550 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
ADRB3 P13945 1/20 0.40
TSHR P16473 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
NFKB1 P19838 1/20 0.40
DRD1 P21728 1/20 0.40
HTR7 P34969 1/20 0.40
ADRA1B P35368 1/20 0.40
DRD3 P35462 1/20 0.40
RAB9A P51151 1/20 0.40
SLC6A3 Q01959 1/20 0.40
SPR P35270 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243804 1.00 OPRK1 (0.44) OPRK1CD274HIF1AADRB1ADRA1A
SCHEMBL12302859 0.87 NQO2 (0.50) OPRK1KDM4EGAAMAPKAPK2OPRD1
SCHEMBL10243841 0.85 ADRB2 (0.39) CD274HIF1AADRA1AADRB2TSHR
SCHEMBL10243687 0.85 CASR (0.56) OPRK1HTR1AADRA2BADRA2CDRD3
SCHEMBL10243996 0.84 CASR (0.42) CD274TSHRSLC6A3KDM4EGAA
SCHEMBL10244285 0.82 ESR1 (0.42) OPRK1CD274HIF1AADRB1ADRA1A
SCHEMBL10243752 0.81 POLB (0.48) ADRB1ADRB2ADRB3RAB9ALMNA
SCHEMBL10282520 0.79 HIF1A (0.54) OPRK1HIF1AADRB1ADRA1AADRB2
SCHEMBL10282560 0.79 HIF1A (0.54) OPRK1HIF1AADRB1ADRA1AADRB2
SCHEMBL10244522 0.79 RRM1 (0.42) CD274ADRB3TSHRLMNARRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 OPRK1 4818/4885CD274 2317/4885HIF1A 2687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.